Table 6Mice plasma and intestine levels for probe compound ML201 following oral gavage administration at 30 mg/kg in mice

Concentration (Mean ± SD)
Time (h)Plasma (ng/mL)μMIntestine (ng/g)μMol/kg
00000
0.0834618.32±4583.9111.5619035.39±15849.7047.65
0.25940.18±609.402.3525010.09±22874.2762.61
0.5116.79±14.450.2962455.66±47746.48156.35
121.89±10.310.05513988.30±14620.2735.02
28.78±8.300.0222065.27±1042.065.17
43.31±2.660.0081410.18±1251.073.53
80.41±0.700.001498.30±543.801.25
120.00±0.0001436.93±1187.983.6
241.60±1.410.004999.18±600.062.5

From: 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.